1428335-27-6

Basic information

• Product Name: C₃₀H₂₄N₆O₃
• Synonyms: C₃₀H₂₄N₆O₃
• CAS NO: 1428335-27-6
• Molecular Weight: 516.559
• Mol File: 1428335-27-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₃₀H₂₄N₆O₃(CAS DataBase Reference)
• NIST Chemistry Reference: C₃₀H₂₄N₆O₃(1428335-27-6)
• EPA Substance Registry System: C₃₀H₂₄N₆O₃(1428335-27-6)

Safety Data

• Hazardous Substances Data: 1428335-27-6(Hazardous Substances Data)

Upstream product

• 1428335-87-8 5-chloro-2-morpholino-6-nitrobenzo[d]oxazole 
• 199293-10-2 5-chloro-6-nitrobenzo[d]oxazole-2-thiol 
• 6358-07-2 2-amino-4-chloro-5-nitrophenol 
• 754214-56-7 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine 
• 1428335-99-2 6-bromo-N-(2-morpholino-5-phenylbenzo[d]oxazol-6-yl)picolinamide 
• 1428335-98-1 C₁₇H₁₇N₃O₂ 
• 1428335-97-0 2-morpholino-6-nitro-5-phenylbenzo[d]oxazole 

Relevant articles and documents

BICYCLIC HETEROCYCLES AS IRAK4 INHIBITORS

The present invention provides bicyclic heterocycle kinase enzyme inhibitor compounds of formula (I), which may be therapeutically useful as kinase inhibitor, more particularly IRAK4 inhibitors. ( I ) in which A, R, R1,R2, m, n and p have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting kinase enzyme, more particularly IRAK4 enzyme.The present invention also provides pharmaceutical formulations comprising at least one of the kinase inhibitor compounds of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.